|
Daily Medical Update
Tuberculosis
Saturday, July 18, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease (2026) - Systematic Review and Meta-analysis
Key Findings
- Adjunctive steroids reduced mortality in adults with tuberculous meningitis, with a risk ratio of 0.83 and 95% confidence interval of 0.72 to 0.95.
- Children did not show a significant mortality reduction with steroids, with a risk ratio of 0.68 and 95% confidence interval of 0.36 to 1.29.
- Steroids did not significantly improve neurologic complications or functional recovery outcomes.
📋 Practice Implication: Use adjunctive corticosteroids as mortality-directed therapy in adults with TB meningitis, while treating pediatric use as a separate decision because benefit was not demonstrated.
|
BMC infectious diseases (2026) - Meta-analysis of Randomized Controlled Trials
Key Findings
- Adjunctive linezolid had a 92% probability of preventing one death per 100 treated patients, with an estimated number needed to treat of 6.
- Linezolid had an 87% probability of preventing one poor neurologic outcome per treated patient.
- The evidence remained low-certainty despite mortality and neurologic disability effect sizes favoring adjunctive linezolid.
📋 Practice Implication: Consider adjunctive linezolid for severe TB meningitis only with explicit discussion of uncertain evidence strength and a plan for toxicity surveillance.
|
BMC infectious diseases (2026) - Systematic Review and Meta-analysis
Key Findings
- MDR/RR-TB continued to increase mortality burden globally despite treatment advances.
- Forecasts to 2030 identified increased regional MDR/RR-TB prevalence risks, with high-risk patterns differing by age, sex, region, and TB burden.
- Regional trend estimates showed ongoing MDR/RR-TB risk that may increase pressure on diagnostic and treatment programs.
📋 Practice Implication: Use local MDR/RR-TB trend data to prioritize rapid resistance testing, drug-susceptibility guided regimens, and regional resource planning.
|
The Indian journal of tuberculosis (2026) - Systematic Review and Meta-analysis
Key Findings
- Loss to follow-up reduced drug-sensitive TB treatment completion in WHO South-East Asia Region countries.
- Loss to follow-up increased risks of treatment failure and emergence of drug-resistant TB strains.
- The meta-analysis of 51 studies showed an increased adherence burden across high-burden settings.
📋 Practice Implication: Build treatment programs around retention interventions, patient tracing, and adherence support rather than relying only on regimen availability.
|
Journal of infection and public health (2026) - Systematic Review and Meta-analysis of Randomized Controlled Trials
Key Findings
- Peripheral neuropathy increased with linezolid compared with standard care, with a risk difference of 0.043.
- Lower linezolid doses or shorter treatment durations reduced adverse events and treatment discontinuation.
- Linezolid-treated patients had fewer unfavorable outcomes despite increased neuropathy risk.
📋 Practice Implication: When using linezolid for MDR/RR-TB, pair the regimen with neuropathy monitoring and dose-duration strategies that limit preventable discontinuation.
|
|
💡
Summary
Recent high-significance tuberculosis evidence emphasizes mortality reduction in tuberculous meningitis, operational risks from MDR/RR-TB and treatment loss to follow-up, and the need to balance linezolid benefit against neurologic toxicity. These findings support risk-stratified TB meningitis care, stronger adherence systems in high-burden regions, and careful monitoring when linezolid is used for resistant disease.
|
|